NovoSeven Approved for Rare Bleeding Disorder
July 8, 2014; Posted by: WeBleed staff
Novo Nordisk gets FDA approval for additional indication.
A release via Zacks.com announced that Novo Nordisk received the United States Food and Drug Administration (FDA) approval for treatment of the rare bleeding disorder Glanzmann’s thrombasthenia. It is the first recombinant pharmaceutical of its kind to be approved for Glanzmann’s which is a platelet deficiency that causes blood abnormalities in the body. NovoSeven’s initial indication was for the the treatment and prevention of bleeding in procedures (surgeries) in adults and children suffering from hemophilia with inhibitors and congenital or acquired hemophilia – and now the company has spread out its label usage.
According to a release issued by Novo Nordisk about this new indication, one out of a million is diagnosed with this disease globally. It is the first time a factor medication has been approved for multiple bleeding disorders.
Photo Credit – Novo Nordisk
webleed.org – your source for bleeding news!
